|Base Year Market Size
|USD XX Billion
|Forecast Year Market Size
|USD XX Billion
|Fastest Growing Market
|Middle East and Africa
Diabetes Management Market Size Anticipated to Touch a CAGR of 4.9 % During the Forecast Period (2022-2027).
Diabetes is recognized as one of the most prevalent chronic diseases across the globe. As per the International Diabetes Federation, 1 in every 11 adults aged 20–79 years are living with diabetes, which is about 463 million. To address the situation, many public and private organizations are implementing different strategies for better management of diabetes, which includes intervention programs, such as lifestyle modification, promotional and educational campaigns, clinical management, and technology-enabled solutions.
The diabetes management market is majorly driven by the improvement in the healthcare sector for the better management of people suffering from diabetes. As diabetes is largely managed through primary care settings and influenced by lifestyle behavior, it functions vital for the primary care and community health providers to play a major role in managing the disease. As per the reports by the International Diabetes Federation, around 10% (USD 760 billion) of the global healthcare expenditure is spent on diabetes management, which is further driving the market growth. Similarly, the introduction of new treatment by leading players is driving the market growth.
Geographically, the diabetes management market is segmented into the Americas, Europe, Asia Pacific, and the Middle East and Africa.
North America is dominating the global market. The region is backed with the presence of major market contributing countries, such as the U.S., Canada, and Mexico. The U.S. is grabbing the highest share in the regional diabetes management market on account of the rising prevalence of diabetes, expanding healthcare infrastructure, rising expenditure power, and increasing healthcare expenditure. As per the CDC, in the U.S., around 34.2 million people are suffering from diabetes, which is further increasing the demand for self-management devices and health care services. In 2016, over 4,100 Diabetes Self-Management Education and Support (DSMES) programs were organized across the U.S. In 2016, about 1.1 million people participated in DSMES programs that are recognized by the American Diabetes Association (ADA) or accredited by the American Association of Diabetes Educators (AADE). Additionally, the CDC is actively working with the National Diabetes Prevention Programs (National DPP) to control the rapidly rising prevalence of diabetes.
In Canada, in 2019, the Diabetes Canada organized round table meetings in Ontario, New Brunswick, and British Columbia to urge support from the government for diabetes management. As per the reports by Diabetes Canada, currently, over 3 million (1 in every 9 adults aged 20 and older) people are living with diagnosed diabetes. About 90% of the cases are of type 2 diabetes. Recently, LMC Healthcare teamed up with Diabetes Canada and INTERVENT International to introduce the country’s first national diabetes prevention program. The program is aimed to investigate the efficiency of intensive, telephonic, and digital lifestyles and to reduce the risk of developing diabetes with structured lifestyle management. The study for the investigation will be funded by the Public Health Agency of Canada. Moreover, Diabetes Canada is working together with other key patient and healthcare organizations, frontline clinicians, and researchers to increase government funding for medical devices in diabetes management.
As per the International Diabetes Federation, in Brazil, over 12 million people were living with diabetes in 2017. To attend to the dire situation, the WHO is undertaking several initiatives, which involve implementing and organizing programs for the prevention, early detection, diagnosis, and management of diabetes and related complications. It is also formulating several rehabilitation programs for the same. Similarly, the national, state, and municipal health authorities of Brazil are actively working to raise awareness regarding diabetes management and are heavily investing for the same. The Brazilian Ministry of Health is offering free of cost medication to tackle diabetes and related conditions. In 2017, around 1 million new cases of diabetes were recorded in Argentine. To tackle the situation, the government of Argentina is organizing advanced training courses for diabetes management, which is further boosting the market growth.
Asia Pacific is the fastest-growing global market and is likely to continue the same during the forecast period. As per the International Diabetes Federation, in 2013, around 382 million people suffered from diabetes, out of which, over 60% of the people are residing in India and China. The rising prevalence can be attributed to the ongoing socio-economic transition that has risen the incidences of both Type 1 and Type 2 diabetes. China is lagging behind in the adoption of AI and Big Data, automated retinal screening (detection of diabetic retinopathy), clinical decision support (detection and monitoring of diabetes), predictive population risk stratification (identification of prevalence of diabetes in subpopulation coupled with risk of complications), and patient self-management tools (dietary tracking devices and activity) for diabetes care and management. However, the rapid development and digital transformation in the field are projected to assist the healthcare professionals in identifying prediabetic patients and diagnose complications related to it. In India, around 60 million people are suffering from diabetes, out of which, about 30 million of the cases are undiagnosed. One of the most promising new opportunities for the market development is provided by the increasing penetration of mobile communications in the country, which is around a billion. Therefore, the Ministry of Health and Family Welfare (MoHFW) collaborated with the WHO to launch a mobile health initiative, named mDiabetes, for the prevention and care of diabetes and to promote a healthy diet and active lifestyle, which is further boosting the market growth.
In Japan, the prevalence of type 2 diabetes is increasing at an alarming rate. As per the national survey, about 12.1% of the people suffered from type 2 diabetes in 2016. Recently, the ‘Educational Hospitalization program’ was introduced to provide close monitoring of the disease, promoting patient education, and decrease the healthcare spending. The program is cost-effective as it is partially covered by the national insurance system. The coverage is around 70–90% depending on age and income.
According to the International Diabetes Federation, in 2019, around 59 million people aged 20–79 are living with diabetes in Europe, and the number is expected to reach 68 million by 2045. The region also comprises the highest number of children and adolescents suffering from type 1 diabetes, which is about 2 million. In the U.K. alone, around 4 million people are suffering from diabetes. To attend to the dire situation, the government in the region has developed a systematic plan for continuous monitoring and evaluation of diabetes. The national diabetes plan is defined as:
In 2013, the government developed and implemented the National Service Framework (NSF) for diabetes in England and Wales for early identification and prevention of diabetes. Similarly, in Scotland, the government has developed the Scottish Diabetes Framework and the Scottish Intercollegiate Guidelines Network (SIGN) for diabetes management. In Germany, the government has developed the Disease Management Programs (DMPs) to tackle the rising prevalence of type 2 diabetes. The program focusses on self-management and secondary prevention of diabetes, which is further boosting the market growth.
In the Middle East and Africa, the prevalence of type 1 diabetes is growing at a concerning rate. As per the International Diabetes Federation, around 3.7 million people (1 in every 430–530 people) aged 19 and above are suffering from type 1 diabetes. The governments in the region have implemented several national diabetes programs to tackle the situation. The market is majorly driven by the rising investments in the research and growing awareness and adoption of diabetes management devices. However, in Africa, the poor healthcare infrastructure, unavailability of advanced treatment options, and low healthcare expenditure is impeding the market growth to some extent.
|By Device Type
|Abbott Laboratories Bayer AG Bristol-Myers Squibb Eli Lilly and Co Sanofi Dexcom Medtronic Novo Nordisk A/S
|U.K. Germany France Spain Italy Russia Nordic Benelux Rest of Europe
|China Korea Japan India Australia Taiwan South East Asia Rest of Asia-Pacific
|Middle East and Africa
|UAE Turkey Saudi Arabia South Africa Egypt Nigeria Rest of MEA
|Brazil Mexico Argentina Chile Colombia Rest of LATAM
|Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
The diabetes management market is bifurcated into device type and therapeutics. The device type is further segmented into blood glucose meters, monitoring devices, diagnostic devices, insulin devices, delivery devices, blood sampling devices, and lancets. The monitoring device segment is expected to grow at a significant rate during the forecast period. This can be attributed to the growing prevalence of diabetes and the rising adoption of monitoring systems. The blood glucose meters segment is anticipated to witness considerable growth on account of the increasing demand for self-care monitoring of glucose levels, growing geriatric population, and expanding online market. The lancets segment is projected to pose remarkable growth by recording a CAGR of 13.23% by 2029. Lastly, the blood sampling devices segment is predicted to register the highest growth during the forecast period due to the rising prevalence of blood disorders and growing demand for plasma from biopharmaceutical companies.
The diagnostic devices is further segmented into hemoglobin A1 C, hemoglobin A1 C kits, and hemoglobin A1 C meters. The diagnostic devices used in the healthcare sector identifies the nature and cause of the disease, which is why, it is extensively used in the hospitals for clinical diagnosis. It is also witnessing huge demand from the pharmaceutical and biopharmaceutical companies for diagnostic tests. The hemoglobin A1 C kit segment is grabbing the highest shares in the global market as it costs less compared to HPLC technology for clinical diagnostic tests. In addition, the kit helps the patients to make an accurate reading and track their hemoglobin levels efficiently.
The insulin delivery devices segment is further divided into insulin pens, insulin pumps, insulin syringes, disposable insulin pens, and reusable insulin pens. The insulin syringes segment is expected to grow at a CAGR of 4.9% during the forecast period. The growth can be attributed to the easy availability of the product, portability of the device, high adoption rate, and cost-efficiency of the treatment. The insulin pens segment is expected to grow at a significant rate as it is simple, accurate, user-friendly, and convenient compared to insulin syringes and vials.
The global therapeutics segment is bifurcated into oral administered drugs and injectables. The therapeutics segment as a whole is largely dominated by human insulin and its catalogs. Currently, the dipeptidyl inhibitor is fueling the market growth and is generating a high revenue owing to its safe nature and once-daily dose regimen. Moreover, strong R&D activities have acquainted the development of safe and efficacious drugs, which is further boosting the market growth.